Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.

Next Previous
Search
Trial Profile

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 28 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by Clinical Trials Registry - India.
    • 21 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Oct 2012 Planned number of patients changed from 1224 to 1424.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top